Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIPAC and Systemic Chemotherapy as a First-line Treatment for Gastric Cancer Peritoneal Metastases
NCT05644249Completed
- Sponsor
- Vilnius University
- Start
- Dec 2022
- Primary completion
- Jun 2025
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Open-label, single-arm trial of cisplatin and doxorubicin in gastric cancer (GC) and peritoneal carcinomatosis (PC), sponsored by Vilnius University. Primary endpoint: Objective Tumor Response at 8 weeks. Started Dec 2022; status: completed.
02
Drugs
cisplatindoxorubicin
03
Conditions
gastric cancer (GC)peritoneal carcinomatosis (PC)
Beyond the preview
Go deeper on NCT05644249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05644249.